Passive vaccination? AstraZeneca spotlights six-month protection with Covid-19 antibody among vulnerable group

New follow-up data suggest that AstraZeneca’s long-acting antibody can protect high-risk populations from contracting Covid-19 for as long as six months, beefing up the case for it as a form of “passive immunization” or “passive vaccination.”